首页  期刊介绍 征稿简则 编委会 期刊征订 广告服务 留言板 English

中国应用生理学杂志 ›› 2016, Vol. 32 ›› Issue (5): 408-412.doi: 10.13459/j.cnki.cjap.2016.05.006

• 研究论文 • 上一篇    下一篇

川芎嗪注射液对慢性阻塞性肺疾病患者肺动脉高压的作用及其机制

赵美平1, 缪初蕾2, 张聪聪1, 郑梦晓1, 黄林静1, 吴成云3, 王万铁1   

  1. 1. 温州医科大学病理生理学教研室, 浙江温州 325035;
    2. 平阳县人民医院呼吸内科, 浙江温州 325000;
    3. 温州医科大学附属第二医院呼吸内科, 浙江温州 325027
  • 收稿日期:2015-06-23 修回日期:2016-05-17 出版日期:2016-09-28 发布日期:2018-06-20
  • 通讯作者: 王万铁,Tel:0577-86689817;E-mail:wwt@wmu.edu.cn E-mail:wwt@wmu.edu.cn
  • 基金资助:
    浙江省中医药科技计划重点项目(2013ZZ011)

The effects and mechanisms of ligustrazine injection on pulmonary arterial hypertension in COPD patients

ZHAO Mei-ping1, MIU Chu-lei2, ZHANG Cong-cong1, ZHENG Meng-xiao1, HUANG Lin-jing1, WU Cheng-yun3, WANG Wan-tie1   

  1. 1. Department of Pathophysiology, Wenzhou Medical University, Wenzhou 325035;
    2. Department of Respiratory Medicine, Pingyang County People's Hospital, Wenzhou 325000;
    3. Department of Respiratory Medicine, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China
  • Received:2015-06-23 Revised:2016-05-17 Online:2016-09-28 Published:2018-06-20
  • Supported by:
    浙江省中医药科技计划重点项目(2013ZZ011)

摘要: 目的:观察川芎嗪注射液对慢性阻塞性肺疾病(COPD)患者肺动脉高压的临床作用并探讨其可能机制。方法:将采集的确诊为COPD的22例患者随机分为2组(n=11): 常规治疗组和川芎嗪治疗组,并随机抽取门诊体检正常者11例作为正常对照组。常规治疗组予以卧床休息、低流量吸氧、支气管舒张剂、糖皮质激素及抗生素等治疗,川芎嗪治疗组在常规治疗基础上加用川芎嗪注射液(60 mg/d静脉点滴),正常对照组不予任何治疗措施,治疗2周后检测3组的肺功能、动脉血气分析及肺动脉压,用敏感硫电极法检测血浆硫化氢(H2S)的浓度。结果:①经过2周治疗后,常规治疗组和川芎嗪治疗组肺功能、动脉血气分析、肺动脉压等各项指标均比治疗前有明显改善,但川芎嗪治疗组优于常规治疗组(P<0.05);②川芎嗪组综合治疗后血浆H2S浓度明显高于治疗前和常规治疗组 (P<0.01)。结论:川芎嗪注射液可能通过升高体内H2S浓度,有效地改善COPD患者肺功能状态。

关键词: 川芎嗪注射液, 肺动脉高压, 低氧高二氧化碳, 慢性阻塞性肺疾病, 硫化氢

Abstract: Objective: To observe the effects of ligustrazine hydrochloride injection(LHI) on pulmonary arterial hypertension in chronic obstructive pulmonary disease(COPD) patients and to investigate its possible mechanisms. Methods: Twenty-two cases of patients with COPD were randomly divided into conventional treatmentgroup (group C) and ligustrazine treatment group(group L), 11 persons were randomly selected from healthy subjects without lung disease served as normal control group(group N). Group C was given bed rest, low flow oxygen inhalation, bronchial diastolic agent, glucocorticoid and antibiotics and other conventional treatment, and group L was added with ligustrazine hydrochloride injection on the above mentioned basis treatment, group N was given no treatment. After 2 weeks, lung function, blood gas analysis and pulmonary arterial pressure were compared among the three groups, and the content of H2S in plasma was tested with sensitive sulfur electrode method. Results: ①After two weeks treatment, in group L and group C pulmonary function, blood gas analysis, pulmonary artery pressure were obviously improved, and group L was better than group C (P<0.05); ② In group L the content of H2S was increased (P<0.01), group C had no significant difference (P>0.05), and there was a significant difference between the two groups (P<0.01). Conclusion: Combination with LHI can effectively improve lung function. LHI mayrelieve hypoxic hypercapnia pulmonary hypertension induced by COPD through raising the content of H2S.

Key words: ligustrazine hydrochloride injection, pulmonaryarterial hypertension, hypoxia-hypercapnia, COPD, H2S

版权所有 © 2015 《中国应用生理学杂志》编辑部
京ICP备16058274号-1
地址:天津市和平区大理道1号,邮编:300050  电话:022-23909086  E-mail:editor@cjap.ac.cn
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn